Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 5/8/2020
SIETES contiene 93082 citas

 
 
<< anterior 21 a 40 de 377 siguiente >>
Presentar resultados
Seleccionar todas
21.Enlace a cita original
Danielsson B, Collin J, Bergman GJ, Borg N, Salmi P, Fastborn J. Antidepressants and antipsychotics classified with torsades de pointes arrhythmia risk and mortality in older adults - a Swedish nationwide study. Br J Clin Pharmacol 2016;81:773-83. [Ref.ID 100181]
22. Cita con resumen
Coupland C, Hill T, Morriss R, Moore M, Arthur A, Hippisley-Cox J. Antidepressant use and risk of cardiovascular outcomes in people aged 20 to 64: cohort study using primary care database. BMJ 2016;352:i1350. [Ref.ID 100143]
23.Enlace a cita original
Thomas SHL, Behr ER. Pharmacological treatment of acquired QT prolongation and torsades de pointes. Br J Clin Pharmacol 2016;81:420-7. [Ref.ID 100138]
24. Cita con resumen
Anónimo. QT interval and drug therapy. Drug Ther Bull 2016;54:33-6. [Ref.ID 100134]
26. Cita con resumen
Anónimo. Hydroxyzine (Atarax, Ucerax): risk of QT interval prolongation and torsade de pointes. Drug Safety Update 2015;8:1. [Ref.ID 99021]
27. Cita con resumen
Villamañán E, Armada E, Ruano M. Prolongación del intervalo QT inducido por fármacos: ¿conocemos sus riesgos?. Med Clin (Barc) 2015;144:269-74. [Ref.ID 98921]
28. Cita con resumen
Degner D. Severe adverse reactions associated with quetiapine. BMJ 2015;350:h1575. [Ref.ID 98872]
29. Cita con resumen
Antoniou T, Hollands S, Macdonald EM, Gomes T, Mamdani MM, Juurlink DN, Canadian Drug Safety and Effectiveness Research Network.. Trimethoprim-sulfamethoxazole and risk of sudden death among patients taking spironolactone. Can Med Assoc J 2015;187:E138-143. [Ref.ID 98851]
30.Tiene citas relacionadas Cita con resumen
Fralick M, Macdonald EM, Gomes T, Antoniou T, Hollands S, Mamdani MM, Juurlink DN, for the Canadian Drug Safety and Effectiveness Research Network (CDSERN). Co-trimoxazole and sudden death in patients receiving inhibitors of renin-angiotensin system: population based study. BMJ 2014;349:g6196. [Ref.ID 98361]
31.Tiene citas relacionadas
Etminan M, Brophy JM. Antibiotics and sudden death in adults taking renin-angiotensin system blockers. BMJ 2014;349:g6242. [Ref.ID 98356]
32. Cita con resumen
Anónimo. Télithromycine: bilan des effets indésirables. Prescrire 2014;34:512-5. [Ref.ID 98075]
33. Cita con resumen
Weeke P, Jensen A, Folke F, Gislason GH, Fosbol EL, Wissenberg M, Lippert FK, Christensen EF, Nielsen SL, Holm E, Kanters JK, Poulsen HE, Kober L, Torp-Pedersen C. Antipsychotics and associated risk of out-of-hospital cardiac arrest. Clin Pharmacol Ther 2014;96:490-7. [Ref.ID 97924]
34. Cita con resumen
Anónimo. Sorafenib (Nexavar) for thyroid cancer. Med Lett Drugs Ther 2014;56:43-4. [Ref.ID 97918]
36.Enlace a cita original
Isbister GK, Page CB. Drug induced QT prolongation: the measurement and assessment of the QT interval in clinical practice. Br J Clin Pharmacol 2013;76:48-57. [Ref.ID 95802]
37.Enlace a cita original Cita con resumen
Celaya Lecea MC, Martínez Basterra J. Medicamentos y prolongación del intervalo QT. Boletín de Información Farmacoterapéutica de Navarra 2013;21:1-7. [Ref.ID 95707]
38. Cita con resumen
Poluzzi E, Raschi E, Koci A, Moretti U, Spina E, Behr ER, Sturkenboom M, De Ponti F. Antipsychotics and torsadogenic risk: signals emerging from the US FDA Adverse Event Reporting System database. Drug Saf 2013;36:467-79. [Ref.ID 95666]
39. Cita con resumen
Kao D, Bartelson BB, Khatri V, Dart R, Mehler PS, Katz D, Krantz MJ. Trends in reporting methadone-associated cardiac arrhythmia, 1997-2011: an analysis of registry data. Ann Intern Med 2013;158:735-40. [Ref.ID 95456]
40. Cita con resumen
Zivin K, Pfeiffer PN, Bohnert ASB, Ganoczy D, Blow FC, Nallamothu BK, Kales HC. Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40 mg . Am J Psychiatry 2013;170:642-50. [Ref.ID 95452]
Seleccionar todas
 
<< anterior 21 a 40 de 377 siguiente >>